V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220005308 | 220002080 | null | null | Curative (C) | 2017-11-22 | 2017-11-24 | Trial Unspecified | Y | N | 220027886 | TRIAL |
| 220005309 | 220002081 | 1.58 | 81.5 | Palliative (P) | null | 2017-01-24 | CYTARABINE | N | N | 220027892 | CYTARABINE |
| 220005310 | 220002081 | null | 80 | Curative (C) | 2017-04-15 | 2017-04-15 | AML17 TRIAL | N | N | 220027892 | AML17 TRIAL |
| 220005311 | 220002081 | 1.81 | 62.4 | Curative (C) | 2017-01-20 | 2017-01-20 | AML17 TRIAL | null | N | 220027892 | AML17 TRIAL |
| 220005312 | 220002081 | 1.83 | 82.4 | Palliative (P) | 2016-01-21 | 2016-01-22 | Trial Unspecified | 1 | N | 220027892 | TRIAL |
| 220005313 | 220002082 | null | 67.55 | Disease modification (D) | 2017-11-05 | 2017-11-05 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 220027902 | CYTARABINE |
| 220005314 | 220002082 | 1.63 | 64.5 | Disease modification (D) | 2017-09-24 | 2017-09-25 | Cytarabine Low Dose | 2 | N | 220027902 | CYTARABINE |
| 220005315 | 220002082 | null | null | Curative (C) | 2016-02-27 | 2016-03-01 | CYTARABINE | N | N | 220027902 | CYTARABINE |
| 220005316 | 220002083 | 1.57 | 0 | Palliative (P) | 2015-03-01 | 2015-03-04 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 220027906 | CYTARABINE |
| 220005317 | 220002084 | null | 80 | Curative (C) | null | 2016-11-17 | Trial Unspecified | Y | null | 220027908 | TRIAL |
| 220005318 | 220011119 | 1.73 | null | Curative (C) | 2013-10-01 | 2013-10-02 | AML17 TRIAL | 1 | null | 220027909 | AML17 TRIAL |
| 220005319 | 220011119 | 1.75 | 86.9 | Palliative (P) | 2017-08-28 | 2017-08-28 | Cytarabine Low Dose | 2 | null | 220027909 | CYTARABINE |
| 220005320 | 220011119 | 1.78 | 0 | Palliative (P) | 2014-12-17 | 2014-12-20 | Cytarabine Low Dose | N | N | 220027909 | CYTARABINE |
| 220005321 | 220002085 | 1.32 | 53 | Not known (9) | 2014-03-11 | 2014-03-11 | Trial Unspecified | Y | N | 220027921 | TRIAL |
| 220005322 | 220002085 | 1.6 | null | Curative (C) | 2017-12-24 | 2017-12-24 | Trial Unspecified | 01 | N | 220027921 | TRIAL |
| 220005323 | 220002086 | 1.68 | null | Curative (C) | 2015-10-21 | 2015-10-28 | AML17 TRIAL | Y | N | 220027927 | AML17 TRIAL |
| 220005324 | 220002086 | 1.83 | 106.1 | Palliative (P) | 2013-06-13 | 2013-06-21 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 220027927 | CYTARABINE |
| 220005325 | 220002087 | 1.71 | null | Curative (C) | 2015-08-01 | 2015-08-03 | AML17 TRIAL | Y | null | 220027929 | AML17 TRIAL |
| 220005326 | 220002087 | null | 64.5 | Not known (9) | null | 2017-01-17 | Cytarabine Low Dose | 02 | N | 220027929 | CYTARABINE |
| 220005327 | 220002087 | 1.7 | null | Curative (C) | 2016-08-18 | 2016-08-18 | AML17 TRIAL | 02 | N | 220027929 | AML17 TRIAL |
| 220005328 | 220002088 | 1.73 | 67.3 | Curative (C) | 2015-11-07 | 2015-11-09 | Trial Unspecified | Y | N | 220027937 | TRIAL |
| 220005329 | 220002089 | null | 88 | Not known (9) | 2015-04-10 | 2015-04-16 | AML17 TRIAL | N | N | 220027939 | AML17 TRIAL |
| 220005330 | 220002090 | null | 76 | Disease modification (D) | 2015-12-31 | 2015-12-31 | AML17 TRIAL | N | null | 220027940 | AML17 TRIAL |
| 220005331 | 220002090 | null | 83 | Adjuvant (A) | 2015-05-02 | 2015-05-02 | AML17 TRIAL | 01 | N | 220027940 | AML17 TRIAL |
| 220005332 | 220002091 | 1.67 | null | Curative (C) | 2017-10-10 | 2017-10-10 | Trial Unspecified | 1 | null | 220027944 | TRIAL |
| 220005333 | 220002092 | null | null | Palliative (P) | 2013-10-06 | 2013-10-21 | Cytarabine Low Dose | null | N | 220027950 | CYTARABINE |
| 220005334 | 220002092 | 1.75 | 70.8 | Curative (C) | 2017-02-20 | 2017-02-20 | AML17 TRIAL | null | null | 220027950 | AML17 TRIAL |
| 220005335 | 220002092 | 0 | null | Palliative (P) | 2013-01-24 | 2013-01-25 | Cytarabine Low Dose | 02 | N | 220027950 | CYTARABINE |
| 220005336 | 220002093 | 1.7 | null | Curative (C) | 2017-06-26 | 2017-06-26 | AML17 TRIAL | Y | N | 220027955 | AML17 TRIAL |
| 220005337 | 220002093 | 1.58 | 94.4 | null | 2015-12-08 | 2015-12-15 | LI-1 TRIAL | 1 | N | 220027955 | TRIAL |
| 220005338 | 220002094 | 1.57 | null | Palliative (P) | 2017-09-16 | 2017-09-23 | CYTARABINE | N | N | 220027959 | CYTARABINE |
| 220005339 | 220011126 | null | 59.6 | Curative (C) | 2016-10-07 | 2016-10-07 | AML17 TRIAL | 01 | N | 220027960 | AML17 TRIAL |
| 220005340 | 220002095 | null | 67.55 | Palliative (P) | 2015-03-14 | 2015-03-14 | Cytarabine Low Dose | N | N | 220027965 | CYTARABINE |
| 220005341 | 220011127 | null | 62.4 | Curative (C) | 2013-03-25 | 2013-03-25 | AML17 TRIAL | null | null | 220027970 | AML17 TRIAL |
| 220005342 | 220011127 | 1.82 | 93 | Not known (9) | 2015-08-18 | 2015-08-18 | AML17 TRIAL | N | N | 220027970 | AML17 TRIAL |
| 220005343 | 220002096 | null | 80.9 | Curative (C) | 2013-02-25 | 2013-02-25 | Trial Unspecified | Y | N | 220027972 | TRIAL |
| 220005344 | 220002097 | null | 91.2 | Radical (R) | 2015-01-03 | 2015-01-10 | Trial Unspecified | Y | N | 220027979 | TRIAL |
| 220005345 | 220002097 | 1.44 | 0 | Palliative (P) | 2016-03-19 | 2016-03-20 | CYTARABINE | 02 | N | 220027979 | CYTARABINE |
| 220005346 | 220002098 | 1.8 | 81.6 | null | 2013-09-17 | 2013-09-17 | CYTARABINE | N | N | 220027982 | CYTARABINE |
| 220005347 | 220011129 | 1.61 | 92 | Curative (C) | 2016-08-26 | 2016-09-06 | LI-1 TRIAL | Y | N | 220027984 | TRIAL |
| 220005348 | 220011129 | null | null | Curative (C) | 2014-11-25 | 2014-11-26 | Cytarabine Low Dose | N | N | 220027984 | CYTARABINE |
| 220005349 | 220002099 | 1.71 | null | Palliative (P) | 2015-07-08 | 2015-07-08 | Cytarabine Low Dose | N | N | 220027986 | CYTARABINE |
| 220005350 | 220002099 | 1.9 | 83.5 | Disease modification (D) | 2016-03-12 | 2016-03-13 | Cytarabine Low Dose | 02 | null | 220027986 | CYTARABINE |
| 220005351 | 220015954 | 1.63 | null | Curative (C) | 2017-12-23 | 2017-12-24 | AML17 TRIAL | 1 | N | 220027990 | AML17 TRIAL |
| 220005352 | 220015954 | 1.74 | 80.1 | Not known (9) | 2013-01-13 | 2013-01-13 | AML17 TRIAL | null | null | 220027990 | AML17 TRIAL |
| 220005353 | 220015954 | 1.79 | 50 | null | 2017-07-07 | 2017-07-09 | LI-1 TRIAL | Y | null | 220027990 | TRIAL |
| 220005354 | 220015954 | 1.63 | 94.2 | null | 2017-05-11 | 2017-05-11 | AML17 TRIAL | 1 | N | 220027990 | AML17 TRIAL |
| 220005355 | 220015954 | 1.59 | 48.8 | Not known (9) | null | 2015-04-11 | Trial Unspecified | N | N | 220027990 | TRIAL |
| 220005356 | 220021991 | 1.83 | 91.5 | Disease modification (D) | 2017-08-17 | 2017-08-17 | AML17 TRIAL | Y | N | 220028014 | AML17 TRIAL |
| 220005357 | 220002100 | 0 | 75.4 | Curative (C) | 2017-08-03 | 2017-08-03 | Cytarabine low (10to20mg/m2) IV/SC | N | N | 220028015 | CYTARABINE |